Canadian scientists have made history with a world first, successfully using focused ultrasound to break through one of the human body’s final frontiers — the blood-brain barrier.
The researchers have unlocked a non-invasive way to deliver medication deep into the brain, opening the door to better treatments for brain tumours, Alzheimer’s, Parkinson’s and more.
The blood-brain barrier has long been an obstacle for doctors trying to treat brain diseases. The barrier is a layer of tightly packed cells that act like plastic wrap, surrounding each of the brain’s blood vessels, protecting them from infections and toxins.
By Brian Shilhavy
Health Impact News
A recent study published in the British Medical Journal reports that taking benzodiazepines, common drugs prescribed for anti-anxiety and insomnia, are associated with a higher risk of Alzheimer’s disease. Common benzodiazepines include: Valium (diazepam), Ativan (lorazepam), Xanax (alprazolam) and Klonopin (clonazepam). The authors of the study reported in the British Medical Journal (BMJ) that the use of benzodiazepines for three months or more was associated with a 51% increased risk of Alzheimer’s disease.
In an accompanying commentary written by Zosia Kmietowicz, it was pointed out that in 2012 the American Geriatrics Society had updated its list of inappropriate drugs for older people to include benzodiazepines, precisely because of their unwanted cognitive side effects. Yet almost half of the elderly population continues to be prescribed these dangerous medications, and are continuing to take them.
In another article appearing with the BMJ study, Michael McCarthy discusses another study just published in JAMA Internal Medicine. This study shows that more than half of patients with advanced dementia in US nursing homes are prescribed medicines of questionable benefit.
Expected New “Blockbuster” Alzheimer’s Drug
Is this why brain supplements are suddenly under attack? Action Alerts!
Does the FDA want to clear away competition for the new drug?
This wouldn’t be the first time this has happened. Just as the first SSRI anti-depressant drug was coming out, the agency banned the amino acid tryptophan. The SSRIs prevented the body from removing serotonin. Tryptophan is used by the body to make serotonin, so the natural supplement was seen as unwanted competition for the drug. The agency used a bad batch of the tryptophan made in Japan as its rather flimsy excuse. Years later, when SSRIs had made billions for drug companies, the agency allowed tryptophan again, but only in a more expensive formulation.
At the present time, Eli Lilly has a potential blockbuster drug for Alzheimer’s in the third and final phase of FDA trials. Currently called solanezumab, if approved it could bring in $7.6 billion in sales by 2024—and that might be a conservative estimate. This is despite evidence the drug doesn’t work that well, at least in later stages of the disease. But if it can be shown to have some benefit for the early stages, that could be enough to make it a huge moneymaker and turn around Eli Lilly’s earnings. The stock has already risen on the prospect. Biogen also has an Alzheimer’s drug in trials. The drug companies view Alzheimer’s as one of their very best potential markets.
The possibility that Alzheimer’s disease (AD) has a microbial aetiology has been proposed by several researchers. Here, we provide evidence that tissue from the central nervous system (CNS) of AD patients contain fungal cells and hyphae. Fungal material can be detected both intra- and extracellularly using specific antibodies against several fungi. Different brain regions including external frontal cortex, cerebellar hemisphere, entorhinal cortex/hippocampus and choroid plexus contain fungal material, which is absent in brain tissue from control individuals. Analysis of brain sections from ten additional AD patients reveals that all are infected with fungi.
Fungal infection is also observed in blood vessels, which may explain the vascular pathology frequently detected in AD patients. Sequencing of fungal DNA extracted from frozen CNS samples identifies several fungal species. Collectively, our findings provide compelling evidence for the existence of fungal infection in the CNS from AD patients, but not in control individuals.
Read More: http://www.nature.com/articles/srep15015
Health Impact News Editor Comments
Cholesterol-lowering statin drugs might be the biggest pharmaceutical scam of this generation. Clearly out-selling all other class of drugs in the market, the lack of science behind the lipid theory of heart disease used to justify lowering cholesterol and prescribing statin drugs has been clearly exposed as false for years now, showing that these cholesterol-lowering drugs are worthless.
But it gets worse. These drugs are very dangerous, and the side effects are becoming more and more well known. For example, there are currently 1400 lawsuits pending against Lipitor, the best-selling drug of all time, for causing Type 2 diabetes in women. And a recent study was just published linking statin drugs to a 27% increased risk for cataracts.
In his recent blog post, Dr. Brownstein warns about an even more serious side effect: brain dysfunction.
About one in three Americans now has diabetes or pre-diabetes. That’s nearly 80 million people, the majority of whom suffer from type 2 diabetes – a preventable and, often, reversible condition.
The problem is that many Americans are unaware that the foods they’re eating could be setting them up for a dietary disaster, and this isn’t their fault. Public health guidelines condemn healthy fats from foods like butter and full-fat dairy and recommend whole grains and cereals – the opposite of what a person with diabetes, or any person really, needs to stay healthy.
For the last 50 years, Americans have been told to eat a high complex carbohydrate, low saturated fat diet. Even diabetics have been told to eat 50 to 60 percent of their daily calories in the form of processed carbs!
Research, including a new study involving dolphins, again suggests that this movement away from traditional full-fat foods is contributing to the rising rates of diabetes and metabolic syndrome across the globe.
Alzheimer’s Association Warns Against Coconut Oil – Member Replies “Coconut Oil Gave us our Father Back!”
Why is it that the Alzheimer’s Association, with revenues of over $230 million per year, has yet to spend even one cent on studying coconut oil?
Article by Brian Shilhavy
CoconutOil.com is one of the leading publishers of information on the Internet regarding coconut oil and Alzheimer’s Disease. As this news of coconut oil’s effectiveness in dementia and Alzheimer’s increases, more and more people are trying coconut oil with their loved ones suffering from Alzheimer’s Disease and dementia and seeing tremendous results.
Thanks to the Internet and social media, this news about coconut oil and Alzheimer’s is spreading very fast, and many remarkable testimonials are being published. Dr. Mary Newport’s story about her husband Steve from 2008 received national attention from CBN earlier this year, and popular TV doctor, Dr. Oz, has also given some positive air time to coconut oil recently.
So naturally the national organization for Alzheimer’s Disease, The Alzheimer’s Association, has to deal with all of the attention that coconut oil is receiving, and they did so last week on their blog. In a blog post by Elizabeth Edgerly, Ph.D., the chief program officer for the Alzheimer’s Association, Northern California and Northern Nevada Chapter, they addressed publicly the issue of Alzheimer’s and coconut oil that so many people apparently had been contacting them about.